Cost–benefit comparison of two proposed overseas programs for reducing chronic Hepatitis B infection among refugees: Is screening essential?  by Jazwa, Amelia et al.
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Background:  Refugees  are  at an  increased  risk  of  chronic  Hepatitis  B virus (HBV)  infection  because  many of
their countries  of origin,  as  well  as host  countries,  have  intermediate-to-high  prevalence  rates.  Refugees
arriving  to the  US  are  also  at risk  of  serious  sequelae  from  chronic  HBV  infection  because  they  are  not
routinely  screened  for  the virus  overseas  or in domestic  post-arrival  exams,  and  may  live in the US  for
years  without  awareness  of  their  infection  status.
Methods: A  cohort  of 26,548  refugees  who  arrived  in Minnesota  and Georgia  during  2005–2010  was
evaluated  to  determine  the prevalence  of chronic  HBV  infection.  This  prevalence  information  was  then
used  in a cost–beneﬁt  analysis  comparing  two variations  of  a proposed  overseas  program  to prevent  or
ameliorate  the  effects  of  HBV  infection,  titled  ‘Screen,  then  vaccinate  or initiate  management’  (SVIM)  and
‘Vaccinate  only’  (VO).  The analyses  were  performed  in 2013.  All values  were  converted  to US  2012  dollars.
Results:  The  estimated  six  year  period-prevalence  of  chronic  HBV  infection  was  6.8%  in the  overall  refugee
population  arriving  to Minnesota  and Georgia  and  7.1%  in  those  ≥6  years  of age.  The  SVIM  program
variation  was  more  cost  beneﬁcial  than  VO.  While  the  up-front  costs  of  SVIM  were  higher  than  VO
($154,084  vs.  $73,758;  n =  58,538  refugees),  the  SVIM  proposal  displayed  a positive  net beneﬁt,  ranging
from  $24  million  to  $130  million  after  only  5 years  since  program  initiation,  depending  on domestic
post-arrival  screening  rates  in the  VO proposal.
Conclusions:  Chronic  HBV  infection  remains  an  important  health  problem  in refugees  resettling  to the
United  States.  An  overseas  screening  policy  for  chronic  HBV  infection  is more  cost–beneﬁcial  than  a  ‘Vac-
cination  only’  policy.  The  major  beneﬁt  drivers  for the  screening  policy  are  earlier medical  management
of  chronic  HBV  infection  and  averted  lost  societal  contributions  from  premature  death.
Published  by Elsevier  Ltd. This  is  an open  access  article  under  the  CC BY-NC-ND  license. Background
Worldwide, Hepatitis B virus (HBV) infections pose a serious
ublic health threat. More than 350 million people worldwide carry
hronic HBV infection, placing them at risk for developing serious
equelae and leading to 600,000 premature deaths annually. The
 Disclaimer:  The opinions expressed by authors contributing to this journal do not
ecessarily reﬂect the opinions of the Centers for Disease Control and Prevention or
he  institutions with which the authors are afﬁliated.
∗ Corresponding author at: 1600 Clifton Road, MS  E-03, Atlanta, GA 30333, United
tates. Tel.: +1 404 639 4462.
E-mail address: wqm7@cdc.gov (B. Maskery).
ttp://dx.doi.org/10.1016/j.vaccine.2015.01.010
264-410X/Published by Elsevier Ltd. This is an open access article under the CC BY-NC-N(http://creativecommons.org/licenses/by-nc-nd/4.0/).
rates of HBV infection vary between countries and regions [1,2].
Some Asian and African countries, many of which are origins for
US-bound refugees, have disease rates exceeding 10% [3]. This leads
to concern for possible importation of chronic HBV infection to
the United States. In 2010, 73,000 refugees resettled to the United
States, with more than half arriving from countries with inter-
mediate (2–7% of the population) to high (>8% of the population)
prevalence of chronic HBV infection [4–6]. Domestic estimates of
chronic HBV infection prevalence in refugees after US arrival range
from 7% to 11% [1,4,7,8].US federal and state governments fund medical care for refugees
overseas and for just under a year after refugee resettlement. After-
wards, refugees may  be eligible for Medicaid, but eligibility varies
by state. Further some states are changing Medicaid rules to expand
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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r narrow eligibility deﬁnitions in response to the Affordable Care
ct. However, regardless of the variable coverage, the federal
overnment and many state governments have a direct ﬁnancial
nterest in mitigating medical conditions arising from chronic HBV
nfections. The Centers for Disease Control and Prevention (CDC)
equires that refugees undergo medical screening overseas to iden-
ify and treat medical conditions deﬁned by regulation as diseases
f public health signiﬁcance. HBV does not fall within these regu-
ations and therefore is not included in routine overseas refugee
creening. In addition, practices with regards to HBV screening
iffer among state refugee agencies. Consequently, an unknown
roportion of refugees remain unaware of their infection because
BV screening is not mandatory [9–11]. The variability in state
ractices for refugee screening may  change based on updated rec-
mmendations by the United States Preventive Services Task Force
o screen asymptomatic adults for HBV in certain high risk groups
12].
Further, many refugees are unvaccinated against HBV prior
o US entry. As required by law, most refugees receive at
east one dose of Hepatitis B vaccine to become legal perma-
ent residents (LPR) one year or more after arrival, but an
nknown number of vaccinees are already infected. These time
aps and inconsistent policies governing overseas and domes-
ic screening and vaccination delay the identiﬁcation of persons
ith chronic HBV infection, allowing disease progression without
edical management and leading to potential risk of transmis-
ion.
Chronic HBV infection is costly, and sequelae to unmanaged
nfection incur high medical expenses. The clinical spectrum
f HBV infection ranges from the inactive hepatitis B sur-
ace antigen (HBsAg) carrier state to the chronic phase with
omplications from chronic hepatitis and cirrhosis [13]. Approx-
mately 15–40% of people who develop chronic HBV infection
re expected to progress to cirrhosis and end-stage liver dis-
ase whereas reactivation is a rare occurrence in inactive carriers
14]. It is estimated that in 2011, per-case drug costs ranged
rom $1500 to $16,000 or more annually, while a liver transplant
osts >$150,000 [15,16]. Preventing infection through vacci-
ation or screening and diagnosis at an earlier stage, when
edical management can prevent or delay serious late-stage
equelae, makes both public health and ﬁnancial sense and has
een demonstrated to be cost-effective in general populations
16–20].
While data are available about the costs and beneﬁts of
BV screening in other populations, no published reports have
ddressed whether costs of screening and vaccinating refugees
verseas will be offset by costs avoided by delaying serious
equelae through early medical management. Some studies indi-
ate that HBV screening and treatment is cost-effective in US
mmigrants. Two studies found it cost-effective to screen immi-
rants from countries with HBV seroprevalence in the range
f >2–3% [17,19]. HBV seroprevalence in US-resettled refugees
alls within or above the range of these studies, indicating
hat a refugee-focused screening and vaccination program may
rove economically beneﬁcial compared to vaccination-only pro-
rams.
The analysis reported here ﬁrst estimates chronic HBV infec-
ion prevalence among newly arrived US refugees in Minnesota
nd Georgia during 2005–2010, and then uses prevalence esti-
ates in a cost–beneﬁt analysis [21]. Two proposed overseas
rogram variations are analyzed: ‘Vaccinate only’ (VO), in which
efugees are vaccinated for Hepatitis B without HBV screening,
ersus ‘Screen, then vaccinate or initiate management’ (SVIM), in
hich refugees are screened for HBV prior to vaccination and HBV-
ositive refugees arrive with a referral to follow up with a liver
pecialist. (2015) 1393–1399
2. Methods
2.1. Epidemiologic methods
This study used original datasets of refugee populations from
the Minnesota Department of Health and Georgia Department of
Public Health for the years 2005–2010. Refugees from Georgia and
Minnesota were included based on availability of data from these
two states. We  treated the 26,548 refugees who arrived to both
states from 82 countries of origin as a single cohort. The original
data were provided in the form of de-identiﬁed refugee records that
included: Hepatitis B surface antigen (HBsAg) screening test results,
a proxy for chronic HBV infection; self-reported and documented
vaccination status (including anti-HBs and anti-HBc testing); and
demographics (age, sex, and country of origin). The study popu-
lation was  restricted to those 6 years of age and older because
transition probabilities from acute to chronic HBV infection sta-
bilize around age 6 and the treatment for children with chronic
HBV infection is different than that for adults [22,23]. The datasets
were reviewed for completeness of the HBsAg screening test vari-
able. Any patient record missing HBsAg screening test results was
excluded from the analysis (14.6% of data), leaving a ﬁnal cohort
of 22,675 observations for analysis. No imputation methods were
used to replace missing data. Refugees with missing test data were
more likely to be older, arrive in Georgia, and originate from South-
east Asia or sub-Saharan Africa.
Univariate analyses were performed to determine population-
wide distributions of demographic variables. The normality of the
continuous variables was assessed, and bivariate analyses were run
to examine HBsAg positivity by region, country, arrival year, sex,
and age.
Descriptive statistics were used to determine prevalence, cal-
culated as the number of chronic HBV cases per 100 refugees.
The estimated number of chronic cases entering the United States
annually and over the 6-year study period was determined by mul-
tiplying the prevalence estimate with total US refugee population
over that same period, estimated by the Department of Homeland
Security [6].
All epidemiologic analyses were performed by using SAS version
9.3 (Cary, NC).
2.2. Economic analysis methods
A decision tree, incorporating a Markov model to represent
changing states of chronic HBV infection (Fig. 1), was  developed
using TreeAge Pro Suite 2009 (Williamstown, MA)  to compare the
costs and beneﬁts of the two  program variations, SVIM and VO. For
SVIM, all refugees are screened for HBV prior to vaccination and
HBV-positive refugees arrive in the United States with guidance for
initiating disease management. For VO, all refugees are vaccinated
with Hepatitis B vaccine without prior HBV screening, although a
proportion undergo screening after US arrival. In the Markov model,
refugees with chronic HBV infection progress annually through the
following disease states depending on immune response and treat-
ment status: inactive carrier, chronic HBV infection, compensated
cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma
(Appendix) [24–26]. No refugee began in decompensated cirrhosis
or hepatocellular carcinoma states during the screening process
overseas because these individuals may  be too sick to undergo
travel for resettlement [24,26]. Death from chronic HBV infection
and sequelae was  an end state in the model. In addition, an age-
speciﬁc background mortality rate was  added to the decision tree
to account for refugees who  die from other causes [27]. The analy-
sis takes a generic health care payer perspective and adds mortality
risk reduction beneﬁts using VSL.
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Fig. 1. Markov model for chronic HBV infection. Note: Individuals begin in one of the following states: chronic HBV infection, delayed clearance, inactive carrier, or com-
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vensated cirrhosis. Individuals may  transition among states or remain in the same
ndividuals may  also transition to a ‘death from background causes’ state from any 
Multiple secondary sources were used to determine the eco-
omic model rate and cost inputs. Two sets of transition rates
ere used to differentiate disease progression patterns: one for
atients undergoing treatment and one for patients who  experi-
nce natural disease progression (Table 1). The annual transition
ates for chronic HBV infection were extracted from published
eports [7–9,25,28,29]. Background mortality for causes of death
ther than HBV sequelae were calculated using the CDC WONDER
atabase [24].
Cost estimates were determined for program implementation
nd administration, medical care, and premature death (Table 2).
he cost of overseas labor was estimated from United Nations
efugee camp labor costs [30]. Cost information for overseas
creening and vaccination supplies and procedures was provided
y CDC [31]. The Physicians Fee and Coding Guide and the Red Book:
harmacy’s Fundamental Reference were used for domestic cost
stimates for medical management and treatment protocols for
hronic HBV infection [32,33]. Treatment protocol costs included
nly the cost of drug therapy. All costs were converted to 2012 US
ollars using the Consumer Price Index [34]. Beneﬁts were esti-
ated by reduced treatment costs and mortality risk reduction,
stimated with a Value of Statistical Life (VSL) of $5,000,000 USD
35,36]. VSL estimates the monetary beneﬁt of reductions in prema-
ure mortality risk for a group of individuals, not the actual dollar
alue of a life [37]. annually throughout the duration of the analysis (5 years, 10 years, or 15 years).
v state except ‘HBV-related death,’ starting in the second year (not shown).
Multiple assumptions were made to construct the economic
model. These included:
1. 100% compliance with overseas screening and vaccination and
100% sensitivity and speciﬁcity of the screening test.
2. Exclusion of acute HBV infections because refugees with an
acute infection would be too ill to resettle to the United
States.
3. For SVIM, HBsAg-positive individuals do not undergo vaccina-
tion [38].
4. For both SVIM and VO proposals, 30% of refugees have docu-
mented vaccination and are not revaccinated. This estimate was
from the documented vaccination status among the Minnesota
and Georgia cohorts.
5. Assumption that 60% of individuals that test positive follow up
with a specialist for treatment and the other 40% go through
natural disease progression; 2% start treatment irrespective of
screening program; and 10% per year drop out of treatment or
monitoring [39,40].
6. Estimations of costs for overseas screening and vaccination using
online and secondary sources [41,42].
7. Use of an average range of drug costs to account for various drug
regimens prescribed to individuals because multiple treatment
regimens exist for chronic HBV infection and related sequelae.
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Table 1
Parameter Estimates for Chronic HBV Prevalence and Annual Disease Transition Rates for Early Treatment-related Progression and Natural Progression of Disease for
Cost-Beneﬁt Model.
Parameter Value Sources
HBsAg positivity (≥6 years of age) 0.071 GDPH, MDHa
Follow-up with liver specialist given chronic HBV diagnosis 0.60 [17]
Initial states for Markov Model among persons HBsAg-positive test results Value Sources
Inactive carrier 0.75 Assumed
Chronic HBV 0.212 Assumed
Compensated cirrhosis 0.038 Assumed
Treatment Probabilities Annual Rate Sources
Inactive carrier → Delayed clearance 0.00425 [19,25]
Inactive carrier → Chronic HBV 0.02 [17,19]
Inactive carrier → Hepatocellular carcinoma 0.003 [17,19]
Chronic HBV → Inactive carrier 0.3 [17,19,25,29]
Chronic HBV → Delayed clearance 0.008 [25]
Chronic HBV → Compensated cirrhosis 0.0045 [18]
Chronic HBV → Hepatocellular carcinoma 0.002 [18]
Chronic HBV → HBV Death 0.00002 Assumed
Compensated cirrhosis → Inactive Carrier 0.165 [18]
Compensated cirrhosis → Decompensated cirrhosis 0.02 [18,28]
Compensated cirrhosis → Hepatocellular carcinoma 0.016 [18,28]
Compensated cirrhosis → HBV Death 0.024 [18]
Decompensated cirrhosis → Liver transplantation 0.06 [17,19]
Decompensated cirrhosis → Hepatocellular carcinoma 0.2 [17,19,28]
Decompensated cirrhosis → HBV death 0.173 [17,19,28]
Hepatocellular carcinoma → Liver transplantation 0.15 [17,19,28]
Hepatocellular carcinoma → HBV death 0.35 [17,19,28]
Liver transplantation → HBV death 0.066 [17,19,28]
Default treatmentb 0.10 Assumed
Natural Progression Probabilities Annual Rate Sources
Inactive Carrier → Delayed Clearance 0.00425 [19,25]
Inactive Carrier → Chronic HBV 0.02 [17,19]
Inactive Carrier → Hepatocellular carcinoma 0.003 [17,19]
Chronic HBV → Inactive carrier 0 Assumed
Chronic HBV → Compensated cirrhosis 0.038 [17,19,25]
Chronic HBV → Hepatocellular carcinoma 0.01 [17,19,25]
Chronic HBV → HBV Death 0.00002 Assumed
Compensated cirrhosis → Decompensated cirrhosis 0.073 [17,19,25,28]
Compensated cirrhosis → Hepatocellular carcinoma 0.034 [17,19,25,28]
Compensated cirrhosis → HBV death 0.049 [17,28]
Decompensated cirrhosis → Hepatocellular carcinoma 0.06 [17,19]
Decompensated cirrhosis → Liver transplantation 0.2 [17,19,28]
Decompensated cirrhosis → HBV death 0.173 [17,19,28]
Hepatocellular carcinoma → Liver transplantation 0.15 [17,19,28]
Hepatocellular carcinoma → HBV death 0.35 [17,19,28]
Liver transplantation transition → HBV death 0.066 [17,19,28]
Enter treatment c 0.02 [20]
a GDPH: Georgia Department of Public Health; MDH: Minnesota Department of Health. This rate accounts for the difference in composition between refugees arriving in
Georgia  and Minnesota relative to refugees arriving in the entire United States.
b Rossi et al. assumed an annual rate of 10% and considered a range of 0-20% in their sensitivity analysis.
c This annual rate of patients entering treatment assumes that patients enter treatment for reasons unrelated to overseas screening or screening during comprehensive
exams shortly after arrival.
Table 2
Cost Estimates for Overseas Screening and Domestic Treatment of Chronic HBV Infection for Cost-Beneﬁt Model.
Program Costs Material Cost (2012 US$) Cost (2012 US$, plus 100% Overhead)* Source
Rapid Screening Test Kit $0.74 $1.49 [41]
Vaccine (3 doses) $0.90 $1.80 [42]
Annual Chronic HBV Treatment Costs Unadjusted Cost Adjusted Cost (2012 US$) Source
Initial  US Medical Visit** $113 $119 [Unpublished data]
Inactive Carrier $750 $790 [17]
Chronic Hepatitis $12,591 $13,267 [32]
Compensated Cirrhosis $13,196 $13,904 [32]
Decompensated Cirrhosis $23,829 $25,108 [32]
Hepatocellular Carcinoma $38,715 $44,048 [28]
Liver Transplant $156,758 $167,143 [17,28]
Transplant Recovery $24,065 $27,218 [17,28]
nd ot
a
c
t* Overhead (includes medical staff costs, transportation, vaccine administration a
** One time cost; includes domestic screening test cost.Beneﬁts and costs were discounted to present values at an
nnual rate of 3%. Net beneﬁts were calculated by subtracting the
ost per person of the SVIM proposal from the VO proposal. Where
he ﬁnal net beneﬁt is positive, the SVIM is more cost–beneﬁcialher costs related to performing the screening test).than the VO proposal. For estimating net beneﬁts of an average
annual cohort of refugees, we  used the average annual number of
refugees entering the United States during the study period (58,538
refugees).
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Table  3
Descriptive Statistics for Study Cohort of Refugees Newly Arriving to Minnesota and
Georgia during 2005-2010.
Variable All Ages (N = 22,675) Ages 6+ (N = 21,409)
AGE, Mean (SD) 26.1 (16.5) 27.4 (16.0)
Age Category (years), n(%)*
<1 184 (0.8) ------
1-5 1,082 (4.8) ------
6-10 2,196 (9.7) 2,196 (10.3)
11-18 5,218 (23.0) 5,218 (24.4)
≥19 13,995 (61.7) 13,995 (65.4)
Female, n (%) 10,966 (48.4) 10,334 (48.3)
REGION, n (%)*
,**
East Asia/Paciﬁc 59 (0.3) 57 (0.3)
Eastern Europe 1,194 (5.3) 1,144 (5.3)
Latin America/Caribbean 348 (1.5) 342 (1.6)
North Africa/Middle East 1,551 (6.8) 1,453 (6.8)
South/Southeast Asia 9,573 (42.2) 8,942 (41.8)
Sub-Saharan Africa 9,922 (43.8) 9,444 (44.1)
Southern Europe 11 (0.0) 11 (0.1)
West Asia 16 (0.1) 15 (0.1)
HBsAg, n (%)
Positive 1,546 (6.8) 1,515 (7.1)
Negative 21,129 (93.2) 19,894 (92.9)
Vaccinated (≥1 dose), n (%) 7,226 (31.9) 6,557 (30.6)
t
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n* Numbers may  not add up to 100% due to rounding.
** Missing = 1.
In addition, we performed sensitivity analyses for time since ini-
iation of the proposals, with the cohort followed for 5 years (base
stimate), 10 years, and 15 years, and the proportion screened in
he United States in the VO arm estimated at 30%, 50% (base esti-
ate), 70%, and 90%. We  do not calculate costs or beneﬁts beyond
hese time periods because Hepatitis B treatment regimens may
hange over the longer term. Currently, even though screening is
ecommended for refugees upon arrival, many refugees receive no
omestic screening; a conservative rate of 50% domestic screening
as used as the base estimate [9–11]. Analyses were also performed
ith and without VSL in the model.
The study was submitted for human subjects determination
t CDC and institutional board reviews at Emory University, the
eorgia Department of Public Health, and the Minnesota Depart-
ent of Health; all four institutions deemed this study exempt from
RB review.
. Results
.1. Prevalence results
The demographics for the Minnesota and Georgia combined
efugee cohort for 2005–2010 were mean age of 26.1 years,
8.4% female, and 86.0% originated from Sub-Saharan African or
outh/Southeast Asian countries (Table 3). During the same time
rame, the estimated 6-year period prevalence of chronic HBV
nfection was 6.8% for the overall arriving refugee population and
.1% in refugees ≥6 years of age. Almost one-third (30.6%) of
efugees ≥6 years of age had received at least one dose of the
BV vaccine before arriving in the United States. An estimated
4,937 refugees age 6 and older entered the United States dur-
ng 2005–2010 with chronic HBV infection (Table 4), an average
f 4156 cases per year.
.2. Cost–beneﬁt analysis results
The SVIM proposal showed a positive net beneﬁt when the
alue of Statistical Life (VSL) was estimated at US $5,000,000. While
he program initiation costs for the SVIM proposal were higher
han those of the VO proposal ($154,084 vs. $73,758, respectively;
 = 58,538 refugees), the SVIM program proposal showed positive (2015) 1393–1399 1397
net beneﬁts after only 5 years of implementation (Table 5). The pos-
itive net beneﬁts resulted from early treatment, which prevented
or delayed serious sequelae and reduced the number of premature
deaths from chronic HBV. In the base case scenario comparing SVIM
to VO with 50% domestic screening, there was a positive net beneﬁt
of $90 million and 20 HBV-associated deaths averted after 5 years
of implementation.
Variations in the economic estimates were attributable to time
since initiation of the screening program and proportion screened
in the United States in the VO proposal. The net beneﬁt was positive
for SVIM over VO in all scenarios except when both VSL was valued
at $0 and domestic screening was 50% or below in the VO program
proposal, indicating that the SVIM proposal is the preferred option
(Table 5). The negative net beneﬁt scenarios used a VSL of $0; there-
fore, VO is preferred only when no monetary value is assigned to
premature death.
As domestic screening rates decreased for the VO proposal, the
overseas SVIM proposal became more cost–beneﬁcial, with SVIM
always the preferred option when VSL is incorporated in the model.
For example, if 70% of refugees were screened in the United States
in the VO proposal, the SVIM proposal would avert 12 prema-
ture deaths and provide an estimated net beneﬁt of $24 million
over the VO proposal, after 5 years from program initiation for an
annual cohort of 58,538 refugees. Yet, in the scenario with only
50% of refugees screened in the United States in the VO proposal,
the SVIM proposal would avert 20 premature HBV-related deaths
and provide an estimated net beneﬁt of $90 million over the VO
proposal, after 5 years from program initiation for the same size
cohort (Table 5).
4. Discussion
Our results indicate that, when mortality reduction beneﬁts
are included in the analysis, higher overseas spending for adding
chronic HBV infection screening to vaccination protocols ($154,084
for screening and vaccination compared with $73,758 for vaccina-
tion only, n = 58,538) yields net beneﬁts ranging from $24 million to
$130 million after only 5 years since program initiation, depending
on domestic screening rates in the VO proposal. Net beneﬁts are
attributable to reduced costs from prevented sequelae and mortal-
ity through earlier diagnosis and medical management of chronic
HBV infection among refugees screened. These beneﬁts continue to
accrue over time because of the reduction in the number of cases
and deaths that would accumulate annual costs for treating seri-
ous sequelae. The only situation in which the VO proposal is more
cost beneﬁcial than the SVIM proposal is when premature loss of
life is not assigned a monetary value and domestic follow-up rates
are assumed to be less than 70%. The analysis also indicates that
HBV infection remains a substantial problem among refugees in
the United States, with rates at intermediate prevalence according
to WHO  guidelines [22].
The main economic beneﬁts from the SVIM proposal come from
early medical management of chronic HBV infection to reduce mor-
bidity and mortality. Knowledge of infection can help refugees
receive early domestic treatment and reduce the probability of
costly serious sequelae. Presently, not all refugees are screened
in the United States with estimates ranging from 31% to 98%
of refugees screened [9–11]. We  accounted for different domes-
tic screening probabilities. With high percentages of individuals
screened domestically after being vaccinated overseas through the
VO proposal, the SVIM proposal was less costly due to the lower
costs of screening overseas. With lower percentages of individuals
screened domestically, net beneﬁts without consideration of VSL
are likely to be negative, but more deaths would be averted via SVIM
relative to VO. Although screening and early treatment is likely to
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Table 4
Estimated Annual Number of Refugees ≥6 years of age entering the United States who are infected with HBV, by arrival year.
Arrival Year HBsAg Prevalence (per 100 refugees) Total refugees entering the US Estimated HBV  cases
2005 7.2 53,738 3,869
2006 8.1 41,053 3,325
2007 7.8 48,281 3,766
2008 7.0 60,193 4,214
2009 5.9 74,654 4,405
2010 6.4 73,311 4,692
6-year Average 7.1 58,538 4,156
6-year Total 7.1 351,230 24,937
Table 5
Net Beneﬁts of ‘Screen, then vaccinate or initiate management’ (SVIM) compared with ‘Vaccinate Only’ (VO) program proposal for HBV infection, with varying domestic
screening rates in VO proposal (2012 US$).
Domestic Screening
rate (%)
Years since
implementa-
tion
VO
cost/refugee
SVIM
cost/refugee
Net Beneﬁt per
refugee, no
mortality
valuationa
Total Net
Beneﬁt, no
mortality
valuationb
Number of
HBV-associated
deaths avertedc
Total net
beneﬁt, with
mortality
valuationd
30 5 $235 $337 ($102) ($6,000,000) 28 $130,000,000
10  $535 $622 ($87) ($5,100,000) 72 $300,000,000
15  $841 $875 ($34) ($1,990,000) 112 $450,000,000
50  (base case) 5 $297 $337 ($40) ($2,300,000) 20 $90,000,000
10  $592 $622 ($30) ($1,800,000) 51 $220,000,000
15  $883 $875 $8 $470,000 80 $320,000,000
70  5 $358 $337 $21 $1,200,000 12 $24,000,000
10  $649 $622 $27 $1,600,000 31 $130,000,000
15  $925 $875 $50 $2,930,000 48 $200,000,000
90  5 $420 $337 $83 $4,900,000 4.1 $24,000,000
10  $706 $622 $84 $4,900,000 10 $49,000,000
15  $968 $875 $93 $5,440,000 16 $70,000,000
a Net beneﬁt = VO cost/person – SVIM cost/person.
b Total net beneﬁt = Net beneﬁt per refugee*size of the refugee cohort (N = 58,538).
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d Mortality Valuation: Value of Statistical Life = $5 million.
e cost-effective, it is not likely to be cost-saving. In addition, it is
mportant to note that the government would be unlikely to recoup
ts investment in early treatment of HBV if refugee insurance or
ealth care payment is transferred from the government to other
ayers after refugees ﬁrst few years in the country.
The US Preventive Health Services recommends HBV screening
or all persons [12]. Overseas screening programs may  be prefer-
ble to improving domestic screening programs for two reasons: (1)
revention of unnecessary vaccination for persons already infected
nd (2) CDC supervises all overseas refugee health programs, but
he responsibilities for domestic program are split up among the
tates.
VSL was an important contributing factor to the cost-savings
f the SVIM proposal. Since the monetary value of mortality risk
eduction cannot be measured directly, we evaluated net beneﬁts
cross a conservative range of estimates.
This study provides novel insights into refugee health screening
nd vaccination protocols. Previous studies have examined the
ost-effectiveness of screening and vaccinating for chronic HBV
nfection, yet there were few studies speciﬁc to refugee populations
nd no studies of overseas screening and vaccination protocols in
his population [15–20,43–46]. In addition, previous cost-analyses
or chronic HBV screening used published estimates for chronic
BV prevalence; our study estimated prevalence information from
bserved, original data sources, which gives greater reliability to
he results [15,17,19].
This study has several limitations. First, it analyzes data from
nly two states, and the refugee populations from Georgia and
innesota may  not be representative of the refugee population
ntering the entire United States. However, prevalence estimates
ere corrected to be representative of all refugees entering thes – SVIM # deaths without discounting.
United States. Second, the analysis omitted young children (<5
years old) because the pediatric treatment for HBV is different from
that of adults and would need a separate analysis [23]. Third, the
challenge of accurately assessing costs of different outcomes of
chronic HBV infection was  difﬁcult because only limited data are
available for the costs of health sequelae of chronic HBV infection,
and domestic costs vary by state and screening facility. Our anal-
ysis included only drug therapy costs for treatment costs, which
may  underestimate the true cost of treatment for HBV infection.
In addition, data are limited and variable for the costs of overseas
HBV screening and vaccination. Finally, the results included in the
analysis represent six years of entry data for refugees; however,
the origin for US-bound refugees may  change in the future. It is
likely that a substantial portion of future US-bound refugees will
also depart from countries with high HBV prevalence rates; how-
ever, widespread adoption of vaccines against HBV may  reduce the
prevalence rate in future refugees.
The ﬁnal limitation affects our fundamental assumption that,
one way or another, refugees would have access to public or private
insurance to pay for their health care subsequent to their initial
resettlement time period of 8 months to a year. This may  not be true
in some states, so implementation of any proposed HBV screening
program would be predicated on refugees being covered for HBV
disease care in the states where they are resettled.
CDC is implementing a pilot project that offers voluntary test-
ing and treatment for certain medical conditions, including chronic
HBV infection, to US-bound refugees at the time of the initial
required medical assessment in Mae  Sot refugee camp in Thailand
[47]. The results of our analysis indicate that expanding HBV
screening along with the existing HBV vaccination protocol would
be cost–beneﬁcial.
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. Conclusion
This study informs the screening protocol of refugees for chronic
BV infection by comparing the costs and beneﬁts of two  over-
eas screening proposals; it also advances the understanding of
he epidemiology of chronic HBV infection prevalence in US-
ound refugees. While the SVIM proposal would increase up-front
xpenditures, net beneﬁts can be observed even after just 5 years
ince implementation because of reduced serious sequelae from
hronic HBV infection through preventing disease or identifying
nfection early. Implementation of an overseas screening proto-
ol could reduce HBV screening and treatment costs in the United
tates and improve health outcomes for refugees with chronic HBV
nfection.
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